US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% SNDK $1,704.16 ▼-0.92%
FinancialContent

MIRA Pharmaceuticals, Inc. - Common Stock (NQ:MIRA)

0.7355 +0.0054 (+0.74%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MIRA Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
Protocol Submitted for IRB Review at a Leading Cancer Research Institution, Advancing the Study Toward Site Initiation 
From Mira Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Is MIRA Pharmaceuticals Stock Gaining Tuesday? ↗
MIRA Pharmaceuticals (NASDAQ: MIRA) stock jumps as MIRA-55 meets key preclinical study milestones for non-opioid inflammatory pain relief. 
Via Benzinga
News headline image
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
Positive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND Submission 
From Mira Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
From Mira Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
Completion of 7-Day Toxicology and Pharmacokinetic Studies Advances Non-Opioid Pain Therapy and Obesity Candidate Development 
From Mira Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain
From MIRA Pharmaceuticals
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction
From MIRA Pharmaceuticals
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC
From MIRA Pharmaceuticals
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
From MIRA Pharmaceuticals
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate
Via ACCESS Newswire
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
What's Going On With MIRA Pharma Stock Tuesday? ↗
MIRA Pharmaceuticals (NASDAQ: MIRA) eyes IND submission for Mira-55 after new 2026 data confirms no CNS side effects. 
Via Benzinga
News headline image
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
Via ACCESS Newswire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
Mag 7 Undercard Stocks: PRSO, MIRA, WHWK, RDZN Surge on AI, Biotech, and Technology News – Full List Inside
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Which stocks are experiencing notable movement on Thursday? ↗
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
MIRA Pharmaceuticals Stock Surges Following Positive Preclinical Data ↗
MIRA Pharmaceuticals shares are trading significantly higher on Thursday following the announcement of new preclinical data for its lead candidate Mira-55. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Dips Over 100 Points; US Crude Oil Inventories Surge ↗
 
Via Benzinga
Topics Stocks
News headline image
Top movers analysis in the middle of the day on 2025-10-16: top gainers and losers in today's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Thursday's session: gap up and gap down stocks ↗
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Dow Surges Over 100 Points; Charles Schwab Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 Next >